Logo
x

Search

Subscribe Now

Reduce

BridgeBio and Origin's Nulibry (fosdenopterin) Receives the US FDA's Approval as the First Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A

BridgeBio and Origin's Nulibry (fosdenopterin) Receives the US FDA's Approval as the First Therapy to Reduce the Risk of Mortality...

  • March 1, 2021
NightWare Receives the US FDA's Approval for the First Medical Device to Stop NightMAres Related to PTSD

NightWare Receives the US FDA's Approval for the First Medical Device to Stop NightMAres Related to PTSD

  • November 11, 2020
Merck and Bayer Receive the US FDA's Priority Review for Vericiguat to Reduce the Risk of CV Death in Patients with Symptomatic Chronic Heart Failure with HFrEF

Merck and Bayer Receive the US FDA's Priority Review for Vericiguat to Reduce the Risk of CV Death in Patients with Symptomatic Ch...

  • July 16, 2020
Baysient to Release iDose Software Technology Platform 1.0 to Reduce the Biosimilar Cost in Market

Baysient to Release iDose Software Technology Platform 1.0 to Reduce the Biosimilar Cost in Market

  • February 28, 2020
Eli Lilly's Trulicity (dulaglutide) Receives the US FDA's Approval to Reduce MACE in T2D Adults

Eli Lilly's Trulicity (dulaglutide) Receives the US FDA's Approval to Reduce MACE in T2D Adults

  • February 24, 2020
Astellas Reports Results of Mirabegron in P-IV PLUS Study to Reduce Overactive Bladder Symptoms in Men

Astellas Reports Results of Mirabegron in P-IV PLUS Study to Reduce Overactive Bladder Symptoms in Men

  • May 6, 2019
Amarin Reports (REDUCE-IT) Trial Results of Vascepa/Vazkepa (icosapent ethyl) for Cardiovascular Diseases

    Amarin Reports (REDUCE-IT) Trial Results of Vascepa/Vazkepa (icosapent ethyl) for Cardiovascular Diseases

    • August 29, 2022
    PharmaShots Interview: Dr. R. Preston Mason, Consultant at Amarin, Corp. Shares Insights from its in vitro Study Results

      PharmaShots Interview: Dr. R. Preston Mason, Consultant at Amarin, Corp. Shares Insights from its in vitro Study Results

      • August 3, 2022
      Corvia Medical Reports Results of Corvia Atrial Shunt in P-III (REDUCE LAP-HF II) Trial for the Treatment of Heart Failure

        Corvia Medical Reports Results of Corvia Atrial Shunt in P-III (REDUCE LAP-HF II) Trial for the Treatment of Heart Failure

        • April 1, 2022
        Amarin Publishes Results of Vascepa (icosapent ethyl) in (REDUCE-IT) Study for the Treatment of Cardiovascular Diseases in JAHA 2022

          Amarin Publishes Results of Vascepa (icosapent ethyl) in (REDUCE-IT) Study for the Treatment of Cardiovascular Diseases in JAHA 20...

          • March 11, 2022
          Cytokinetics Presents Results of Omecamtiv Mecarbil in P-III (METEORIC-HF) Trial for Heart Failure with Reduced Ejection Fraction at ACC 2022

            Cytokinetics Presents Results of Omecamtiv Mecarbil in P-III (METEORIC-HF) Trial for Heart Failure with Reduced Ejection Fraction...

            • February 16, 2022
            Cytokinetics Receives the US FDA Acceptance of NDA for Omecamtiv Mecarbil to Treat Heart Failure with Reduced Ejection Fraction

              Cytokinetics Receives the US FDA Acceptance of NDA for Omecamtiv Mecarbil to Treat Heart Failure with Reduced Ejection Fraction

              • February 7, 2022
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.